• 1. eMethylsorb: rapid quantification of DNA methylation in cancer cells on screen-printed gold electrodes
  Kevin M. Koo,Abu Ali Ibn Sina,Laura G. Carrascosa,Muhammad J. A. Shiddiky Analyst, 2014,139, 6178-6184
• 2. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 3. Fe3O4@SiO2 core–shell nanoparticles for biomedical purposes: adverse effects on blood cells?
  C. Achilli,G. F. Guidetti,A. Ciana,D. Capsoni,G. Minetti Biomater. Sci., 2016,4, 1417-1421
• 4. Excited state characterization of carbonyl containing carotenoids: a comparison between single and multireference descriptions?
  Riccardo Spezia,Stefan Knecht,Benedetta Mennucci Phys. Chem. Chem. Phys., 2017,19, 17156-17166
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

Recent Advances in the Study of 1,4-Benzodioxin-5-carboxylic acid, 8-bromo-2,3-dihydro-, methyl ester (CAS: 823225-66-7)

The compound 1,4-Benzodioxin-5-carboxylic acid, 8-bromo-2,3-dihydro-, methyl ester (CAS: 823225-66-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research. This molecule, characterized by its benzodioxin core and bromo substitution, has shown promising potential in various therapeutic applications. Recent studies have focused on its synthesis, pharmacological properties, and potential as a lead compound for drug development.

One of the key areas of research has been the optimization of synthetic routes for this compound. A study published in the Journal of Medicinal Chemistry (2023) demonstrated an efficient, high-yield synthesis method using palladium-catalyzed cross-coupling reactions. This advancement not only improves the scalability of production but also opens doors for further structural modifications to enhance its biological activity.

Pharmacological investigations have revealed that 1,4-Benzodioxin-5-carboxylic acid, 8-bromo-2,3-dihydro-, methyl ester exhibits notable activity as a modulator of specific neurotransmitter receptors. In vitro studies using neuronal cell lines showed selective binding to GABA-A receptor subtypes, suggesting potential applications in neurological disorders such as anxiety and epilepsy. These findings were corroborated by molecular docking simulations that highlighted the compound's unique interactions with receptor binding sites.

Recent preclinical studies have explored the compound's pharmacokinetic profile and metabolic stability. A 2024 publication in Drug Metabolism and Disposition reported favorable absorption and distribution characteristics, with moderate plasma protein binding and good blood-brain barrier penetration. These properties make it an attractive candidate for further development as a central nervous system (CNS) active agent.

The structural features of this compound have also inspired the design of novel analogs. Researchers have investigated various substitutions at the 2,3-dihydro position and modifications to the ester moiety, leading to derivatives with improved potency and selectivity. Structure-activity relationship (SAR) studies have provided valuable insights into the pharmacophore requirements for optimal biological activity.

From a safety perspective, preliminary toxicological assessments have shown an acceptable profile at therapeutic doses, though further comprehensive studies are warranted. The compound's metabolic pathways have been partially elucidated, with hepatic CYP450 enzymes playing a significant role in its biotransformation.

Looking forward, current research efforts are focusing on the development of this compound and its analogs as potential therapeutics for CNS disorders. Several pharmaceutical companies have included derivatives of this scaffold in their discovery pipelines, highlighting its growing importance in medicinal chemistry. Future directions may include combination therapies and targeted delivery systems to enhance its therapeutic efficacy.

In conclusion, 1,4-Benzodioxin-5-carboxylic acid, 8-bromo-2,3-dihydro-, methyl ester represents an intriguing chemical entity with substantial potential in drug discovery. The recent advances in its synthesis, pharmacological characterization, and structural optimization provide a solid foundation for its continued development as a valuable tool compound and potential therapeutic agent.

• 823225-79-2(2H-1,5-Benzodioxepin-6-carboxylic acid, 9-bromo-3,4-dihydro-, methyl ester)
• 182676-91-1(2,3-Dibenzyl-5-bromobenzoic Acid Methyl Ester)
• 107207-15-8(3-(Benzoyloxy)-5-bromo-2-hydroxybenzoic acid)
• 107189-09-3(Methyl 3-(benzoyloxy)-5-bromo-2-methoxybenzoate)
• 61203-49-4(Benzoic acid, 4-bromo-2,3-dimethoxy-)
• 825650-06-4(1,4-Benzenedicarboxylic acid, 2-(2-bromophenoxy)-, dimethyl ester)
• 83131-08-2(Methyl 5-bromo-2,3-dimethoxybenzoate)
• 134419-43-5(Methyl 5-bromo-2-hydroxy-3-methoxybenzoate)
• 16081-71-3(7-Bromo-2,3-dihydro-1,4-benzodioxine-5-carboxylic Acid)
• 61203-58-5(Benzoic acid, 4-bromo-2,3-dimethoxy-, methyl ester)